| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008643526 |
| P356 | DOI | 10.1186/S40425-016-0200-7 |
| P8608 | Fatcat ID | release_p5sdhuiiw5hujandga5sstqo5a |
| P932 | PMC publication ID | 5171656 |
| P698 | PubMed publication ID | 28031824 |
| P50 | author | William J. Murphy | Q91170042 |
| Ellen E Sparger | Q92224645 | ||
| Arta Monjazeb | Q114522999 | ||
| Jaime Modiano | Q42696815 | ||
| Michael Kent | Q57423407 | ||
| P2093 | author name string | Mingyi Chen | |
| Jesus I Luna | |||
| Jiwon S Park | |||
| Robert B Rebhun | |||
| Robert J Canter | |||
| Sita S Withers | |||
| William T N Culp | |||
| P2860 | cites work | The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation | Q83177010 |
| Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma | Q83370677 | ||
| Cancer immunotherapy | Q84228162 | ||
| Of mice and men | Q86812264 | ||
| Comparative functional characterization of canine IgG subclasses | Q86832715 | ||
| Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma | Q86914238 | ||
| Comparative analysis of cancer genes in the human and chimpanzee genomes | Q24541311 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Mouse xenograft models vs GEM models for human cancer therapeutics | Q24657555 | ||
| Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering | Q27022477 | ||
| Interactions between the microbiota and the immune system | Q27028155 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| How drugs are developed and approved by the FDA: current process and future directions | Q28239492 | ||
| The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway | Q28476288 | ||
| Comparative oncology: what dogs and other species can teach us about humans with cancer | Q28607304 | ||
| Genomic responses in mouse models poorly mimic human inflammatory diseases | Q29547718 | ||
| Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans | Q73042654 | ||
| Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases | Q73182772 | ||
| Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma | Q73832694 | ||
| Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs | Q74325198 | ||
| Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice | Q75312804 | ||
| Efficient generation of canine bone marrow-derived dendritic cells | Q80213474 | ||
| CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma | Q80352090 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Cohabiting family members share microbiota with one another and with their dogs | Q31115660 | ||
| The domestic dog genome | Q33198667 | ||
| Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression | Q33520381 | ||
| Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates | Q33595267 | ||
| Isolation and characterization of canine natural killer cells | Q33605114 | ||
| Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B | Q33741869 | ||
| Spontaneously occurring tumors of companion animals as models for human cancer | Q33927360 | ||
| Neoplasia in the chimpanzee (Pan spp.). | Q33948099 | ||
| MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. | Q33975551 | ||
| Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases | Q34098525 | ||
| Basic data on the hematology, serum biochemistry, urology, and organ weights of beagle dogs | Q34122645 | ||
| In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study | Q34194680 | ||
| Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer | Q34355792 | ||
| Cancer immunotherapy in veterinary medicine: Current options and new developments | Q34500896 | ||
| The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease | Q34540297 | ||
| Overview of immune system development in the dog: comparison with humans | Q35012713 | ||
| Breed-specific hematological phenotypes in the dog: a natural resource for the genetic dissection of hematological parameters in a mammalian species | Q35055251 | ||
| Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach | Q35126999 | ||
| Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade | Q35184928 | ||
| CANINE NEOPLASIA. A PROTOTYPE FOR HUMAN CANCER STUDY | Q35398925 | ||
| BRAF Mutations in Canine Cancers | Q35656395 | ||
| Spontaneous and genetically engineered animal models; use in preclinical cancer drug development | Q35761437 | ||
| Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy | Q35833912 | ||
| The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine | Q35928383 | ||
| Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma | Q35931188 | ||
| Prognostic and predictive markers in canine tumours: rationale and relevance. A review | Q36196363 | ||
| Intestinal commensal microbes as immune modulators | Q36451342 | ||
| Canine DLA-79 gene: an improved typing method, identification of new alleles and its role in graft rejection and graft-versus-host disease | Q36708751 | ||
| Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure | Q36781992 | ||
| Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline | Q36873386 | ||
| Cancer clinical trials: development and implementation | Q36976795 | ||
| Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations | Q37020305 | ||
| Translation of new cancer treatments from pet dogs to humans | Q37059654 | ||
| Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells | Q37160693 | ||
| Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential | Q37212371 | ||
| Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma | Q37796409 | ||
| Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment | Q38005395 | ||
| The effect of neutering on the risk of mammary tumours in dogs--a systematic review | Q38014591 | ||
| Naturally occurring cancers in dogs: insights for translational genetics and medicine | Q38220802 | ||
| Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology | Q38220804 | ||
| The role of clinical trials in veterinary oncology | Q38245001 | ||
| Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk | Q38550359 | ||
| Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies | Q38749141 | ||
| NCR1 is an activating receptor expressed on a subset of canine NK cells | Q38756870 | ||
| Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. | Q38758789 | ||
| CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia | Q38813257 | ||
| Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets | Q39051491 | ||
| Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells | Q39133062 | ||
| Prognostic value of tumour-associated macrophages in canine mammary tumours. | Q39624921 | ||
| Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. | Q41009948 | ||
| Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life | Q41479487 | ||
| NCR1+ cells in dogs show phenotypic characteristics of natural killer cells | Q41642818 | ||
| Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models | Q41905175 | ||
| Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County | Q44203800 | ||
| Age-related variations in hematologic and plasma biochemical test results in Beagles and Labrador Retrievers | Q44661726 | ||
| Factors influencing canine mammary cancer development and postsurgical survival | Q45125144 | ||
| Effect of ovariohysterectomy at the time of tumor removal in dogs with benign mammary tumors and hyperplastic lesions: a randomized controlled clinical trial | Q46278669 | ||
| Epizootiologic characteristics of canine and feline leukemia and lymphoma | Q46493172 | ||
| Breed differences in development of anti-insulin antibodies in diabetic dogs and investigation of the role of dog leukocyte antigen (DLA) genes | Q46684702 | ||
| Breed incidence of lymphoma in a UK population of insured dogs. | Q47363042 | ||
| TP53 gene mutations in canine osteosarcoma | Q47643652 | ||
| Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. | Q51697865 | ||
| Progress of non-human primate animal models of cancers. | Q51727690 | ||
| Comparison of three-view thoracic radiography and computed tomography for detection of pulmonary nodules in dogs with neoplasia. | Q53165600 | ||
| CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. | Q54519853 | ||
| Host related risk factors for canine osteosarcoma. | Q55067718 | ||
| Extensive interbreed, but minimal intrabreed, variation of DLA class II alleles and haplotypes in dogs | Q57322754 | ||
| Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor | Q57434297 | ||
| Spontaneous canine mammary tumors. A model for monoclonal antibody diagnosis and treatment of human breast cancer | Q61232470 | ||
| Plasma biochemistry values of young beagle dogs | Q67965071 | ||
| Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW) | Q72202507 | ||
| Canine lymphoma as a potential model for experimental therapeutics | Q72312156 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 97 | |
| P577 | publication date | 2016-12-20 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Canine cancer immunotherapy studies: linking mouse and human | |
| P478 | volume | 4 |
| Q89494995 | A Role for Dogs in Advancing Cancer Immunotherapy Research |
| Q101038825 | A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| Q57279498 | Adoptive cell transfer: new perspective treatment in veterinary oncology |
| Q46132734 | AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. |
| Q38371241 | Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model |
| Q89830584 | Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer |
| Q61817963 | Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells |
| Q90331515 | Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation |
| Q90698764 | Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells |
| Q89967245 | Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence |
| Q92151739 | Companion Animals as Models for Inhibition of STAT3 and STAT5 |
| Q90087112 | Development of transplantable B-cell lymphomas in the MHC-defined miniature swine model |
| Q91871648 | Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology |
| Q61448151 | Exploring the Potential Utility of Pet Dogs With Cancer for Studying Radiation-Induced Immunogenic Cell Death Strategies |
| Q47283164 | First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready? |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q89815118 | Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes |
| Q49829334 | Immunotherapy for Dogs: Running Behind Humans |
| Q99551380 | Improving human cancer therapy through the evaluation of pet dogs |
| Q55058455 | Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma. |
| Q90064248 | Minimal PD-1 expression in mouse and human NK cells under diverse conditions |
| Q39323096 | Nanomaterial-Enabled Cancer Therapy |
| Q96689740 | OMIP-065: Dog Immunophenotyping and T-Cell Activity Evaluation with a 14-Color Panel |
| Q88678430 | Obesity as an immune-modifying factor in cancer immunotherapy |
| Q47164846 | Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. |
| Q52657766 | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. |
| Q92874029 | The Dog Model in the Spotlight: Legacy of a Trustful Cooperation |
| Q90737508 | The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors |
| Q59350793 | The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif |
| Q56898750 | White paper on microbial anti-cancer therapy and prevention |
Search more.